Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.

ABSTRACT:

Purpose

We evaluated 5-year oncologic and functional outcomes of hemigland cryoablation of localized prostate cancer.

Materials and methods

We reviewed the records of 160 consecutive men who underwent hemigland cryoablation of localized prostate cancer. Recurrent and/or residual clinically significant prostate cancer was defined as Grade Group 2 or greater on followup biopsy. A prostate specific antigen nadir plus 2 ng/ml according to the Phoenix criteria was used to define biochemical failure. Radical treatment was defined as any whole gland therapy. Treatment failure was defined as any radical and/or whole gland treatment, systemic therapy initiation, metastasis or prostate cancer specific mortality. The study primary end point was treatment failure-free survival. The seco

SUBMITTER: Oishi M 

PROVIDER: S-EPMC9235523 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature